Table 1 from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Key Points

• FoundationOne Liquid CDx demonstrates clinical validity for detecting BRAF V600E mutations in colorectal cancer, supporting its use in precision medicine.
• The study highlighted key demographic and clinical characteristics in LBx test-evaluable subsets, emphasizing the importance of accurate mutation identification.
• Assessment utilized clinical data from colorectal cancer patients to determine the effectiveness of FoundationOne Liquid CDx in mutation detection.
• The findings call for the broader adoption of liquid biopsy techniques to improve treatment outcomes in colorectal cancer management.